SecBot SecBot
SECBOTREPLAY Home › Report › ONCY

ONCY · Oncolytics Biotech announced translational data from the GOBLET and…

Oncolytics Biotech, Inc. · PRESS-RELEASE filed May 22, 2026 at 09:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 22, 2026 at 09:00 ET

Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showing pelareorep expands pre-existing tumor-reactive immune cells and activates anti-tumor responses in KRAS-mutant pancreatic cancer and early-stage breast cancer. The data are mechanistic and non-clinical, with no new efficacy results or regulatory milestones disclosed.

  • Translational data from GOBLET (pancreatic cancer) and AWARE-1 (breast cancer) to be presented at ASCO 2026 (May 29-June 2).
  • Data show pelareorep induces antiviral immune response, expands virus-specific T cells, and activates tumor-specific T cells.
  • In pancreatic cancer, expansion of pre-existing TIL clones in blood correlated with reductions in tumor volume.
  • T-cell receptor sequencing confirmed expansion of mutant KRAS-specific T-cell clones.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access